Related coverage linked through entity extraction aliases.
Mar 17, 2026
Recent research identifies novel genetic causes for rare movement and neurodegenerative disorders, including CD99L2 variants in spastic ataxia, PPP2R5C as an Alzheimer's biomarker, and toxic polyglycine proteins in GGC repeat expansion diseases.
Mar 11, 2026
LIXTE Biotechnology Holdings appointed Sidney Braun as CEO of its Liora Technologies Europe Ltd. subsidiary to lead advancement of the LiGHT System proton therapy platform following the company's November 2025 acquisition of Liora's assets.
Feb 18, 2026
LIXTE Biotechnology Holdings appointed Sidney Braun as CEO of its Liora Technologies Europe Ltd. subsidiary on February 18, 2026. Braun brings over 20 years of healthcare experience and facilitated LIXTE's November 2025 acquisition of Liora's assets.
Feb 13, 2026
LIXTE Biotechnology Holdings is developing LB-100, a first-in-class PP2A inhibitor designed to enhance chemotherapy and immunotherapy effectiveness across multiple cancer types, with proof-of-concept trials underway.
